BACKGROUND: Evidence suggests that increasing intensity of rehabilitation results in better motor recovery. Limited evidence is available on the effectiveness of an interactive virtual reality gaming system for stroke rehabilitation. EVREST was designed to evaluate feasibility, safety and efficacy of using the Nintendo Wii gaming virtual reality (VRWii) technology to improve arm recovery in stroke patients. METHODS: Pilot randomized study comparing, VRWii versus recreational therapy (RT) in patients receiving standard rehabilitation within six months of stroke with a motor deficit of > or =3 on the Chedoke-McMaster Scale (arm). In this study we expect to randomize 20 patients. All participants (age 18-85) will receive customary rehabilitative treatment consistent of a standardized protocol (eight sessions, 60 min each, over a two-week period). OUTCOME MEASURES: The primary feasibility outcome is the total time receiving the intervention. The primary safety outcome is the proportion of patients experiencing intervention-related adverse events during the study period. Efficacy, a secondary outcome measure, will be measured by the Wolf Motor Function Test, Box and Block Test, and Stroke Impact Scale at the four-week follow-up visit. From November, 2008 to September, 2009 21 patients were randomized to VRWii or RT. Mean age, 61 (range 41-83) years. Mean time from stroke onset 25 (range 10-56) days. CONCLUSIONS: EVREST is the first randomized parallel controlled trial assessing the feasibility, safety, and efficacy of virtual reality using Wii gaming technology in stroke rehabilitation. The results of this study will serve as the basis for a larger multicentre trial. ClinicalTrials.gov registration# NTC692523.
RCT Entities:
BACKGROUND: Evidence suggests that increasing intensity of rehabilitation results in better motor recovery. Limited evidence is available on the effectiveness of an interactive virtual reality gaming system for stroke rehabilitation. EVREST was designed to evaluate feasibility, safety and efficacy of using the Nintendo Wii gaming virtual reality (VRWii) technology to improve arm recovery in strokepatients. METHODS: Pilot randomized study comparing, VRWii versus recreational therapy (RT) in patients receiving standard rehabilitation within six months of stroke with a motor deficit of > or =3 on the Chedoke-McMaster Scale (arm). In this study we expect to randomize 20 patients. All participants (age 18-85) will receive customary rehabilitative treatment consistent of a standardized protocol (eight sessions, 60 min each, over a two-week period). OUTCOME MEASURES: The primary feasibility outcome is the total time receiving the intervention. The primary safety outcome is the proportion of patients experiencing intervention-related adverse events during the study period. Efficacy, a secondary outcome measure, will be measured by the Wolf Motor Function Test, Box and Block Test, and Stroke Impact Scale at the four-week follow-up visit. From November, 2008 to September, 2009 21 patients were randomized to VRWii or RT. Mean age, 61 (range 41-83) years. Mean time from stroke onset 25 (range 10-56) days. CONCLUSIONS: EVREST is the first randomized parallel controlled trial assessing the feasibility, safety, and efficacy of virtual reality using Wii gaming technology in stroke rehabilitation. The results of this study will serve as the basis for a larger multicentre trial. ClinicalTrials.gov registration# NTC692523.
Authors: James R Carey; Teresa J Kimberley; Scott M Lewis; Edward J Auerbach; Lisa Dorsey; Peter Rundquist; Kamil Ugurbil Journal: Brain Date: 2002-04 Impact factor: 13.501
Authors: Deborah S Nichols-Larsen; P C Clark; Angelique Zeringue; Arlene Greenspan; Sarah Blanton Journal: Stroke Date: 2005-06-09 Impact factor: 7.914
Authors: C Gowland; P Stratford; M Ward; J Moreland; W Torresin; S Van Hullenaar; J Sanford; S Barreca; B Vanspall; N Plews Journal: Stroke Date: 1993-01 Impact factor: 7.914
Authors: Andreas R Luft; Richard F Macko; Larry W Forrester; Federico Villagra; Fred Ivey; John D Sorkin; Jill Whitall; Sandy McCombe-Waller; Leslie Katzel; Andrew P Goldberg; Daniel F Hanley Journal: Stroke Date: 2008-08-28 Impact factor: 7.914
Authors: Christian Dohle; Klaus Martin Stephan; Jakob T Valvoda; Omid Hosseiny; Lutz Tellmann; Torsten Kuhlen; Rüdiger J Seitz; Hans-Joachim Freund Journal: Exp Brain Res Date: 2010-12-25 Impact factor: 1.972
Authors: Gustavo Saposnik; Robert Teasell; Muhammad Mamdani; Judith Hall; William McIlroy; Donna Cheung; Kevin E Thorpe; Leonardo G Cohen; Mark Bayley Journal: Stroke Date: 2010-05-27 Impact factor: 7.914
Authors: Alberto L Morán; Cristina Ramírez-Fernández; Victoria Meza-Kubo; Felipe Orihuela-Espina; Eloísa García-Canseco; Ana I Grimaldo; Enrique Sucar Journal: J Med Syst Date: 2015-08-12 Impact factor: 4.460
Authors: Geoffrey Sithamparapillai Samuel; Nicodemus Edrick Oey; Min Choo; Han Ju; Wai Yin Chan; Stanley Kok; Yu Ge; Antonius M Van Dongen; Yee Sien Ng Journal: Singapore Med J Date: 2016-06-17 Impact factor: 1.858